Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer
Status:
Completed
Trial end date:
2014-09-29
Target enrollment:
Participant gender:
Summary
The clinical hypothesis of this study is that the first-line treatment with the combination
of panitumumab and paclitaxel will provide benefit for patients with metastatic or current
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello